Cabaletta Bio, Inc. (CABA) stock
CABANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.28−0.05 (-3.76%)
Close on Nov 13, 2026Market cap $217.02MP/E –Yield –
Cabaletta Bio cash
Cash and short-term investments held at the end of each period.
Cabaletta Bio's cash was $299.38M at Sep 30, 2026. For fiscal 2025 it was $133.60M, down 18.5% from the year before. The highest annual figure on record is $241.25M in fiscal 2023.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $133.60M | -18.5% |
| FY2024 | Dec 31, 2024 | $163.96M | -32.0% |
| FY2023 | Dec 31, 2023 | $241.25M | +126.4% |
| FY2022 | Dec 31, 2022 | $106.55M | -12.8% |
| FY2021 | Dec 31, 2021 | $122.22M | +12.5% |
| FY2020 | Dec 31, 2020 | $108.66M | -20.2% |
| FY2019 | Dec 31, 2019 | $136.20M | +312.5% |
| FY2018 | Dec 31, 2018 | $33.02M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $299.38M | +87.2% |
| Q2 FY2026 | Jun 30, 2026 | $225.10M | +15.6% |
| Q1 FY2026 | Mar 31, 2026 | $116.64M | -11.5% |
| Q4 FY2025 | Dec 31, 2025 | $133.60M | -18.5% |
| Q3 FY2025 | Sep 30, 2025 | $159.93M | -12.6% |
| Q2 FY2025 | Jun 30, 2025 | $194.68M | -4.2% |
| Q1 FY2025 | Mar 31, 2025 | $131.83M | -41.1% |
| Q4 FY2024 | Dec 31, 2024 | $163.96M | -32.0% |
| Q3 FY2024 | Sep 30, 2024 | $183.01M | +11.3% |
| Q2 FY2024 | Jun 30, 2024 | $203.23M | +15.3% |
| Q1 FY2024 | Mar 31, 2024 | $223.85M | +138.5% |
| Q4 FY2023 | Dec 31, 2023 | $241.25M | +126.4% |
| Q3 FY2023 | Sep 30, 2023 | $164.39M | +91.4% |
| Q2 FY2023 | Jun 30, 2023 | $176.33M | +82.1% |
| Q1 FY2023 | Mar 31, 2023 | $93.85M | -14.1% |
| Q4 FY2022 | Dec 31, 2022 | $106.55M | -12.8% |
| Q3 FY2022 | Sep 30, 2022 | $85.90M | -28.0% |
| Q2 FY2022 | Jun 30, 2022 | $96.81M | -5.8% |
| Q1 FY2022 | Mar 31, 2022 | $109.21M | +7.0% |
| Q4 FY2021 | Dec 31, 2021 | $122.22M | +12.5% |
| Q3 FY2021 | Sep 30, 2021 | $119.26M | +1.0% |
| Q2 FY2021 | Jun 30, 2021 | $102.81M | -16.5% |
| Q1 FY2021 | Mar 31, 2021 | $102.03M | -22.1% |
| Q4 FY2020 | Dec 31, 2020 | $108.66M | -20.2% |
| Q3 FY2020 | Sep 30, 2020 | $118.07M | +66.2% |
| Q2 FY2020 | Jun 30, 2020 | $123.18M | +273.1% |
| Q1 FY2020 | Mar 31, 2020 | $131.00M | – |
| Q4 FY2019 | Dec 31, 2019 | $136.20M | – |
| Q3 FY2019 | Sep 30, 2019 | $71.04M | – |
| Q4 FY2018 | Dec 31, 2018 | $33.02M | – |
See a number that looks wrong?